Patents Assigned to Union Therapeutics A/S
-
Patent number: 11866445Abstract: The present invention relates to novel substituted dihydrothienopyrimidines with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.Type: GrantFiled: May 16, 2022Date of Patent: January 9, 2024Assignee: UNION therapeutics A/SInventor: Jens Larsen
-
Publication number: 20230087354Abstract: The present invention relates to novel substituted azetidine dihydrothienopyridines with phosphodiesterase inhibitory activity, and to their use in therapy, and to pharmaceutical compositions comprising the compounds and to methods of treating diseases with the compounds (I)Type: ApplicationFiled: June 8, 2022Publication date: March 23, 2023Applicant: UNION therapeutics A/SInventors: Mark ANDREWS, Daniel Rodriguez GREVE, Bjarne NØRREMARK
-
Patent number: 11529361Abstract: The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhoea and C. difficile associated colitis.Type: GrantFiled: November 6, 2020Date of Patent: December 20, 2022Assignee: UNION therapeutics A/SInventors: Morten Otto Alexander Sommer, Rasmus Vendler Toft-Kehler, Daniel Jean Jacques Simon
-
Patent number: 11384096Abstract: The present invention relates to novel substituted azetidine dihydrothienopyridines with phosphodiesterase inhibitory activity, and to their use in therapy, and to pharmaceutical compositions comprising the compounds and to methods of treating diseases with the compounds (I)Type: GrantFiled: December 14, 2018Date of Patent: July 12, 2022Assignee: UNION therapeutics A/SInventors: Mark Andrews, Daniel Rodriguez Greve, Bjarne Nørremark
-
Patent number: 11370799Abstract: The present invention relates to novel methods for the preparation of 1,3-benzo-dioxole heterocyclic compounds and intermediates for the same. The compounds are useful as PDE4 inhibitors.Type: GrantFiled: December 16, 2016Date of Patent: June 28, 2022Assignee: Union therapeutics A/SInventors: Allan Carsten Dahl, Gitte Holm Jensen, Tine Marianne Duus
-
Patent number: 11365204Abstract: The present invention relates to novel substituted dihydrothienopyrimidines with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.Type: GrantFiled: September 20, 2018Date of Patent: June 21, 2022Assignee: Union therapeutics A/SInventor: Jens Larsen
-
Patent number: 11331327Abstract: The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus, in particular Staphylococcus aureus, and Streptococcus, in particular Streptococcus pyogenes. Grain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.Type: GrantFiled: June 12, 2020Date of Patent: May 17, 2022Assignee: UNION therapeutics A/SInventors: Emilie Flora Aurore Delavenne, Daniel Jean Jacques Simon, Morten Otto Alexander Sommer, Rasmus Vendler Toft-Kehler
-
Patent number: 11331289Abstract: The present invention relates to a new topical composition comprising niclosamide and/or oxyclozanide and to the use of said composition for the treatment or prevention of pyoderma or dermatitis in non-human mammals.Type: GrantFiled: September 14, 2018Date of Patent: May 17, 2022Assignees: CEVA SANTE ANIMALE, UNION THERAPEUTICS A/SInventors: Jérôme Guyonnet, Claudine Zemiriline, Pascal Butty
-
Patent number: 11324761Abstract: The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus, in particular Staphylococcus aureus, and Streptococcus, in particular Streptococcus pyogenes. Grain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.Type: GrantFiled: June 12, 2020Date of Patent: May 10, 2022Assignee: UNION therapeutics A/SInventors: Emilie Flora Aurore Delavenne, Daniel Jean Jacques Simon, Morten Otto Alexander Sommer, Rasmus Vendler Toft-Kehler
-
Patent number: 11324708Abstract: The invention relates to a method of treating a viral infection caused by or associated with SARS-CoV-2 in a subject, the method comprising administering to the subject by inhalation intraorally and/or intranasally a therapeutically effective amount of a formulation comprising niclosamide, or a pharmaceutically acceptable salt thereof, and a cyclodextrin.Type: GrantFiled: May 25, 2021Date of Patent: May 10, 2022Assignee: UNION therapeutics A/SInventors: Morten Otto Alexander Sommer, Rasmus Toft-Kehler, Anne Katrine Toft-Kehler, Günter Ditzinger, Mads Jellingsoe, Philippe Andres, Matthias Manne Knopp
-
Patent number: 11299497Abstract: The present invention relates to novel substituted tetrahydropyran dihydrothienopyrimidines with phosphodiesterase inhibitory activity, and to their use in therapy, and to pharmaceutical compositions comprising the compounds and to methods of treating diseases with the compounds (I).Type: GrantFiled: December 14, 2018Date of Patent: April 12, 2022Assignee: UNION therapeutics A/SInventors: Jens Larsen, Simon Feldbaek Nielsen, Peter Andersen
-
Patent number: 11292799Abstract: The present invention relates to novel substituted azetidine dihydrothienopyrimidines with phosphodiesterase inhibitory activity, and to their use in therapy, and to pharmaceutical compositions comprising the compounds and to methods of treating diseases with the compounds (I).Type: GrantFiled: December 14, 2018Date of Patent: April 5, 2022Assignee: UNION THERAPEUTICS A/SInventors: Mark Andrews, Daniel Rodriguez Greve, Jens Larsen
-
Patent number: 11285164Abstract: The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus, in particular Staphylococcus aureus, and Streptococcus, in particular Streptococcus pyogenesGrain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.Type: GrantFiled: June 12, 2020Date of Patent: March 29, 2022Assignee: UNION therapeutics A/SInventors: Emilie Flora Aurore Delavenne, Daniel Jean Jacques Simon, Morten Otto Alexander Sommer, Rasmus Vendler Toft-Kehler
-
Patent number: 11220514Abstract: The present invention relates to novel methods for the preparation of 1,3-benzodioxole heterocyclic compounds of formula (I). The compounds are useful as PDE4 inhibitors.Type: GrantFiled: June 19, 2018Date of Patent: January 11, 2022Assignee: UNION therapeutics A/SInventors: Allan Carsten Dahl, Johan Eriksson Bajtner, Esben Paul Krogh Olsen, Bjørn Metzler
-
Patent number: 11213533Abstract: This invention relates to combination products comprising an amidine selected from dibromopropamidine and diminazene or a pharmaceutically acceptable salt or solvate thereof; and a tetracycline anti-bacterial agent. The combination products are suitable for use in the treatment of bacterial infections or diseases.Type: GrantFiled: September 14, 2017Date of Patent: January 4, 2022Assignee: UNION Therapeutics A/SInventors: Morten Otto Alexander Sommer, Rasmus Toft-Kehler
-
Publication number: 20210386674Abstract: The present invention relates to modified release tablet formulations for oral administration of phosphodiesterase inhibitors. The pharmaceutical formulations are useful in the treatment, prevention or alleviation of dermal diseases or conditions.Type: ApplicationFiled: January 14, 2020Publication date: December 16, 2021Applicant: UNION therapeutics A/SInventors: Marianne RASMUSSEN, Karin Green HØY, Carsten RAVN, Jari PAJANDER, Poul E. BERTELSEN, Gitte Pommergaard PEDERSEN
-
Patent number: 11045434Abstract: The invention relates to a method of treating a viral infection caused by or associated with SARS-CoV-2 in a subject, the method comprising administering to the subject by inhalation intraorally and/or intranasally a therapeutically effective amount of a formulation comprising niclosamide, or a pharmaceutically acceptable salt thereof, and a cyclodextrin.Type: GrantFiled: November 13, 2020Date of Patent: June 29, 2021Assignee: UNION therapeutics A/SInventors: Morten Otto Alexander Sommer, Rasmus Toft-Kehler, Anne Katrine Toft-Kehler, Günter Ditzinger, Mads Jellingsoe, Philippe Andres, Matthias Manne Knopp
-
Patent number: 10857164Abstract: The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhoea and C. difficile associated colitis.Type: GrantFiled: October 1, 2019Date of Patent: December 8, 2020Assignee: UNION therapeutics A/SInventors: Morten Otto Alexander Sommer, Ramus Vendler Toft-Kehler, Daniel Jean Jacques Simon
-
Patent number: 10758553Abstract: The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus, in particular Staphylococcus aureus, and Streptococcus, in particular Streptococcus pyogenes. Grain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.Type: GrantFiled: September 7, 2018Date of Patent: September 1, 2020Assignee: UNION therapeutics A/SInventors: Emilie Flora Aurore Delavenne, Daniel Jean Jacques Simon, Morten Otto Alexander Sommer, Rasmus Vendler Toft-Kehler
-
Patent number: 10463680Abstract: The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhea and C. difficile associated colitis.Type: GrantFiled: May 27, 2016Date of Patent: November 5, 2019Assignee: UNION therapeutics A/SInventors: Morten Otto Alexander Sommer, Rasmus Vendler Toft-Kehler, Daniel Jean Jacques Simon